Format

Send to

Choose Destination
Nanotechnology. 2016 Nov 18;27(46):464001. Epub 2016 Oct 13.

EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA delivery.

Author information

1
Pharmaceutical Biotechnology, Center for System-based Drug Research, and Center for NanoScience (CeNS), Ludwig-Maximilians-Universität München, Butenandtstrasse 5-13, D-81377 Munich, Germany.

Abstract

Antitumoral siRNA and miRNA delivery was demonstrated by epidermal growth factor receptor (EGFR) targeted oligoaminoamide polyplexes. For this purpose, the T-shaped lipo-oligomer 454 was used to complex RNA into a core polyplex, which was subsequently functionalized with the targeting peptide ligand GE11 via a polyethylene glycol (PEG) linker. To this end, free cysteines on the surface of 454 polyplex were coupled with a maleimide-PEG-GE11 reagent (Mal-GE11). Resulting particles with sizes of 120-150 nm showed receptor-mediated uptake into EGFR-positive T24 bladder cancer cells, MDA-MB 231 breast cancer cells and Huh7 liver cancer cells. Furthermore, these formulations led to ligand-dependent gene silencing. RNA interference (RNAi) triggered antitumoral effects were observed for two different therapeutic RNAs, a miRNA-200c mimic or EG5 siRNA. Using polyplexes modified with a ratio of 0.8 molar equivalents of Mal-GE11, treatment of T24 or MDA-MB 231 cancer cells with miR-200c led to the expected decreased proliferation and migration, changes in cell cycle and enhanced sensitivity towards doxorubicin. Delivery of EG5 siRNA into Huh7 cells resulted in antitumoral activity with G2/M arrest, triggered by loss of mitotic spindle separation and formation of mono-astral spindles. These findings demonstrate the potential of GE11 ligand-containing RNAi polyplexes for cancer treatment.

PMID:
27736810
DOI:
10.1088/0957-4484/27/46/464001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOP Publishing Ltd.
Loading ...
Support Center